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presence of 4r tau in AD pathologies may be underestimated 
when rD4 is used. However, anti-4r (available from Cosmo 
Bio Co., Ltd.) raised against rD4 peptide with N279D sub-
stitution stained both wild-type and deamidated 4r tau, and 
strongly stained rD3+/rD4− tangles and smearing tau 
fragments in sarkosyl-insoluble fraction of AD brain [2].
It was reported that rD3 stained abundant ghost tangles 
in entorhinal cortex and tangles in CA1, but failed to stain 
fine processes of tangles and threads [3], while rD4 failed 
to detect ghost tangles in entorhinal cortex [3]. To under-
stand these findings, we examined the influence of protease 
on immunoreactivity. paraffin sections of AD brains were 
treated with 10 μg/mL proteinase K (pro-K) for 30 min 
after autoclaving (Ac) and formic acid (FA) treatment. rD3 
staining was strongly enhanced (Fig. 1a, b). Conversely, 
rD4 immunoreactivity almost completely disappeared 
after pro-K treatment (Fig. 1c, d). Not only ghost tangles 
but also rD3−/rD4+ tangles and their processes became 
rD3-positive after pro-K treatment (Fig. 1a, b), strongly 
suggesting that the rD3 epitope was buried in tau filaments 
of intracellular tangles and threads, and was exposed by 
pro-K treatment. Contrary to expectation, anti-4r stain-
ing was also enhanced by pro-K treatment (Fig. 1e, f). It is 
possible that the recognition site of anti-4r is distinct from 
that of rD4 and is exposed by pro-K treatment of sections. 
Anti-4r antibody may recognize the carboxyl-half of the 
antigen peptide, while rD4 recognizes the amino-terminal 
half around N279. pro-K treatment was also effective in 
immunostaining of free-floating AD sections with a lower 
concentration.
To confirm these findings biochemically, sarkosyl-
insoluble fractions from two AD brains were treated with 
trypsin or pro-K, then immunoblotted with rD3, rD4, 
anti-4r and anti-ps396 (Fig. 1g–j). rD3 strongly stained 
many bands and smears, as seen with ps396 (Fig. 1g, j), 
Isoform-specific tau antibodies rD3 and rD4 are useful 
tools for investigating expression and localization of three-
repeat (3r) and four-repeat (4r) tau isoforms. recently, 
transition from 3r to 4r tau in Alzheimer’s disease (AD) 
was proposed based on immunohistochemical studies with 
rD3 and rD4 [3]. Here, we show that two factors influence 
immunoreactivity to these antibodies. First, deamidation at 
the rD4 epitope abrogates immunoreactivity to rD4, and 
second, presentation of rD3 and rD4 epitopes is recipro-
cally affected by protease. Asparagine at position 279 in the 
rD4 epitope is predominantly deamidated to aspartic acid 
in pathological tau in AD brains [2, 4]. Consequently, the 
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Fig. 1  a–f Immunostaining of 
AD sections after Ac and FA 
treatment before (a, c, e) and 
after (b, d, f) pro-K treat-
ment, using rD3 (a, b), rD4 
(c, d) and anti-4r (e, f). Bar 
100 μm. g–j Immunoblots of 
sarkosyl-insoluble tau from two 
AD brains, before (Con) and 
after treatments with trypsin or 
pro-K, using rD3 (g), rD4 (h), 
anti-4r (i) and ps396 (j). k–l 
Computed cross-section through 
a paired helical filament (k) 
[reproduced from ref. [1], with 
permission of the publisher], 
a predicted folding model of 
3r and 4r tau in pHF (l). rD3 
and rD4 epitopes are indicated 
by blue and red, respectively. 
4r tau specific insertion is 
indicated by underlining. The 
deamidation site N279 is indi-
cated by asterisks. phospho-
rylation of ser396 is indicated. 
possible trypsin, pronase and 
pro-K cleavage sites are indi-
cated in green, purple and dark 
blue arrows, respectively. The 
protease-resistant domain of 
pHF is indicated as PHF-core
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whereas rD4 only labeled the 64/68 kDa doublet and some 
fragments at ~25 kDa (Fig. 1h). Anti-4r strongly stained 
the smears and fragments (Fig. 1i), suggesting that tau in 
these rD4-negative anti-4r-positive bands and smears is 
deamidated at N279. The weak rD4 and strong anti-4r 
immunoreactivities were completely abolished after trypsin 
or pro-K treatment (Fig. 1h, i). This result is inconsistent 
with the immunohistochemistry, but protease sensitivity is 
likely different in fixed tissues. In contrast, the rD3 epitope 
was retained in the fragments, and rD3 strongly reacted 
with the protease-resistant 10–25 kDa bands after trypsin 
or pro-K treatment (Fig. 1g). ps396 epitope was removed 
by pro-K but not trypsin, suggesting a location outside the 
pHF core. Trypsin may not cleave the Ksp site because 
of phosphorylation of ser396. These results demonstrate 
reciprocal effects of protease treatment on rD3 and rD4 
epitopes, indicating that rD4 epitope in tau in AD is sus-
ceptible to proteases, while rD3 epitope is highly resistant.
These results are consistent with previous findings. Wis-
chik et al. identified two types of amino acid sequences, 
QpGGGKVQIVYK… (3r tau) and IKXVpGG… (4r tau), 
in 12-kDa tau fragment comprising the pronase-resistant 
core of pHFs [6] (see Fig. 1k). We identified HQpGGG…
(3r tau) and HVpGGG… (4r tau) in 7–15 kDa trypsin-
resistant fragments of pHF-tau in AD brains [5]. In both 
cases, 3r and 4r tau isoforms were detected, but the 
4r tau N-terminus lacked the rD4 epitope. Based on 
these observations and a computed cross-section of pHF 
(Fig. 1k) [1], we propose a schematic model of tau folding 
in pHF (Fig. 1l). Analysis of the cross-sectional density in 
the pHF core on electron micrographs indicates the pres-
ence of two C-shaped morphological units, which corre-
spond to the two strands of pHF, each with three domains 
(Fig. 1k) [1]. The rD3 epitope is buried in the pHF core 
and is normally masked by the N- or C-terminal region of 
tau, but is exposed in ghost tangles and/or in pHFs attacked 
by proteases. The rD4 epitope, which is mostly deami-
dated in pHF, is located slightly outside the core, where 
it can be digested by proteases (Fig. 1l). This model can 
explain the epitope masking of rD3 and rD4 and the 
reciprocal effects of degradation or protease treatment on 
the immunoreactivities.
This study indicates that differential presentation of 
epitopes can occur as a result of folding and processing, 
even when the epitopes are located in close proximity. Tau 
in pHFs appears to be processed gradually by intracellular 
proteases and more extensively in extracellular space dur-
ing AD progression. We suggest that changes in immunore-
activity to antibodies reflect aging of tau in tangles or pHFs, 
which are composed of both 3r and 4r tau isoforms. We 
also show that pro-K treatment of sections after Ac and FA 
treatment is useful for unmasking buried epitopes.
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